Research Journal of Oncology Open Access

  • Journal h-index: 4
  • Journal CiteScore: 0.30
  • Journal Impact Factor: 0.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Commentry - (2023) Volume 7, Issue 4

Navigating the Metabolic Frontier: Response to Ketogenic Diet in Colorectal Cancer
Rahul Ahuja*
Department of Bioscience, Malaysian College of Science and Technology, Malaysia
*Correspondence: Rahul Ahuja, Department of Bioscience, Malaysian College of Science and Technology, Malaysia, Email:

Received: 29-Nov-2023, Manuscript No. IPRJO-24-18702; Editor assigned: 01-Dec-2023, Pre QC No. IPRJO-24-18702 (PQ); Reviewed: 15-Dec-2023, QC No. IPRJO-24-18702; Revised: 20-Dec-2023, Manuscript No. IPRJO-24-18702 (R); Published: 27-Dec-2023, DOI: 10.36648/iprjo-7.4.39


Colorectal Cancer (CRC) ranks among the most prevalent and formidable malignancies worldwide, prompting relentless exploration of innovative therapeutic strategies. One such frontier gaining attention is the ketogenic diet, a high-fat, and low-carbohydrate nutritional approach known for its metabolic impact. This article delves into the unfolding narrative of the response to the ketogenic diet in colorectal cancer, exploring the molecular underpinnings, clinical implications, and the evolving landscape of metabolic interventions. The ketogenic diet, characterized by a significant reduction in carbohydrate intake and an increase in healthy fats, induces a state of ketosis. In this metabolic state, the body relies on ketone bodies, produced from fats, as a primary energy source instead of glucose. Beyond its well-established role in managing conditions like epilepsy and obesity, the ketogenic diet has emerged as a subject of intrigue in the realm of cancer therapeutics, including colorectal cancer.

The response to the ketogenic diet in colorectal cancer is deeply rooted in the intricate dance of metabolic pathways. Tumour cells often exhibit a heightened reliance on glucose, a phenomenon known as the Warburg effect. The ketogenic diet, by restricting glucose availability, aims to create a metabolic environment less favourable for cancer cell proliferation. Preclinical studies exploring the response to the ketogenic diet in colorectal cancer cell lines and animal models have yielded promising signals. Reduced tumour growth, altered gene expression patterns, and increased sensitivity to certain chemotherapeutic agents have been observed in response to the ketogenic diet. While preclinical data spark optimism, the translation of ketogenic diet strategies into clinical practice for colorectal cancer patients presents both challenges and opportunities. Limited clinical trials exploring the efficacy of the ketogenic diet as a standalone therapy are currently available, and existing evidence is often anecdotal or derived from small observational studies. Challenges include the need for standardized dietary protocols, patient adherence, and the potential for unintended nutritional deficiencies. Moreover, the heterogeneity of colorectal cancer poses a challenge in identifying patient subgroups most likely to benefit from metabolic interventions.

The most promising avenue for the ketogenic diet in colorectal cancer may lie in its integration with standard therapeutic modalities. Combining the diet with traditional treatments, such as surgery, chemotherapy, or targeted therapies, holds potential for synergistic effects. The metabolic vulnerabilities induced by the ketogenic diet may sensitize cancer cells to the cytotoxic effects of conventional treatments, offering a twopronged attack on tumour cells. As researchers tread the metabolic frontier, the response to the ketogenic diet in colorectal cancer continues to unfold. On-going clinical trials seek to provide more robust evidence regarding the diet’s safety, feasibility, and efficacy in diverse patient populations. Molecular profiling and biomarker discovery efforts aim to identify the patients most likely to derive benefit from metabolic interventions. The metabolic reprogramming of colorectal cancer through the ketogenic diet represents a captivating chapter in the evolving narrative of cancer therapeutics. While challenges persist, the potential for a paradigm shift in the management of colorectal cancer, leveraging the interplay between metabolism and malignancy, keeps the scientific community and patients alike attentive to the unfolding discoveries on this metabolic frontier



Conflict Of Interest

The author’s declared that they have no conflict of interest.

Citation: Ahuja R (2023) Navigating the Metabolic Frontier: Response to Ketogenic Diet in Colorectal Cancer. Res J Onco. 7:39.

Copyright: © 2023 Ahuja R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.